Ferruccio De Lorenzo graduated from Federico II Medical School, Naples, Italy in 1990 and qualified as a specialist in General (Internal) Medicine (EEA certificate) in 1996. In 2002 he was awarded a Ph.D and Diploma in Medicine from the National Heart & Lung Institute, Imperial College of Science, Technology and Medicine in London, UK. In 2002 he founded Euroclinics, partner agency of the CHD collaborative group to implement the National Service Framework for Coronary Heart Disease. In 2003 he obtained the Clinician Scientist Award recognition for the post at the Thrombosis Research Institute from the National Co-ordinating Centre for Research Capacity and Development (Department of Health) and the National Clinician Scientist Monitoring Committee. In 2005 has been appointed Consultant Physician in General Medicine and Prevention of Vascular Disorders at the Chelsea and Westminster Hospital NHS Trust in London. In January 2008 the Faculty of Medicine- King's College London, and the Chelsea and Westminster Hospital have nominated Dr De Lorenzo for the Clinical Senior Lectureship awarded by the Higher Education Funding Council for England, the Department of Health, and the UK Clinical Research Collaboration. From 2009 Clinical Director of the Heart Health Check programme at the Knaresborough Place Medical Chambers in London(www.londonmedicalchambers.com/ferruccio_de_lorenzo.asp). He is a member of the British Hypertension Society,International Society of Vascular Health (ISVH) and HEART UK, BMA, and Royal College of Physicians. His publications include over 50 original articles [35 first author], 11 reviews [7 first author], 10 reports & chapters [6 first author], 1 book [ first author]
Chelsea and Westminster Healthcare NHS Trust, London:
*Prevention of atherosclerosis in patients living with HIV. Vascular Health and Risk Management 2009:5 287–300
* Ritonavir at 100 mg once and twice daily decreases HDL and CD36 expression but only twice daily dosing increases triglycerides and adipophilin expression: potential effect of low dose ritonavir on cardiovascular risk. Clin Pharmacol Ther. 2009 Apr; 85(4):375-8.
* UK Screening Plans. The Lancet 2008; 372: 447-8
* Metabolic-inflammatory changes, and accelerated atherosclerosis in HIV patients: Rationale for preventative measures. Curr Med Chem. 2008;15(28):2991-9
* Scavenger Receptor A and CD36 Are Implicated in Mediating Platelet Activation Induced by Oxidized Low- Density Lipoproteins.
Arterioscler Thromb Vasc Biol. 2007;27:2491-2492
* Risk of accelerated coronary heart diseases in HIV-infected patients: Statin Therapy-Evidence Beyond Lipid Lowering Contributing to Plaque Stability. Curr Med Chem 2006; 13: 3385-93.
Ashford Hospital NHS Trust , Ashford Middlesex, London: Low Molecular Weight Heparin in 100 patients with Heart Failure. Am Heart Journal 2002; 143 (4): 689-95;
Central Middlesex Hospital NHS Trust, London:
* Dobutamine stress echocardiography in 350 CHD patients after myocardial revascularization. Int J Cardiol 2002; 83 (2): 119-124.
Thrombosis Research Institute:
* Association of overall adiposity rather than body mass index is associated with lipids and procoagulant factors. Thrombosis and Haemostasis 1998; 80 (4): 603-606;
* Blood coagulation in patients with chronic heart failure with evidence for a hypercoagulable state and potential for pharmacological intervention. Drugs 2003, 63 (6): 565-576; *Prevention of venous thromboembolism in general surgery. Bailliere's Clin Haematol 1998; 11 (3): 605-619; *Low Molecular Weight Heparins in Cardiovascular Medicine. Minerva Cardioangiologica 2005; 53(6):585-603; *Anticoagulation in patients with cancers- Facts and figures. Current Medicinal Chemistry- Anti Cancer Agents. 2006; 6 (6): 579-587;
Personal Web Links
Forward
Print
5 online sources [ view sources ]
The Thrombosis Research Institue
